HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection

The interferon-free combination of once-daily faldaprevir 120 mg, twice-daily deleobuvir 600 mg, and weight-based ribavirin was evaluated in two Phase III studies (HCVerso1, HCVerso2) in hepatitis C virus genotype-1b-infected, treatment-naïve patients, including those ineligible for peginterferon (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarrazin, Christoph, Castelli, Francesco, Andreone, Pietro, Buti, Maria, Colombo, Massimo, Pol, Stanislas, Calinas, Filipe, Puoti, Massimo, Olveira, Antonio, Shiffman, Mitchell, Stern, Jerry O, Kukolj, George, Roehrle, Michael, Aslanyan, Stella, Deng, Qiqi, Vinisko, Richard, Mensa, Federico J, Nelson, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125810/
https://www.ncbi.nlm.nih.gov/pubmed/27920566
http://dx.doi.org/10.2147/CEG.S111116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125810/
https://www.ncbi.nlm.nih.gov/pubmed/27920566
http://dx.doi.org/10.2147/CEG.S111116

Ejemplares similares